Drug Trial Radar · NCT05067335
A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis
Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
327
Actual
Start
Oct 21, 2021
Primary completion
Nov 9, 2023
Study completion Nov 9, 2023
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Oct 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 55 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the effect of treatment with romosozumab for 6 months compared with placebo on the percent changes in bone mineral density (BMD) at the lumbar spine, at the total hip and femoral neck in postmenopausal Chinese women with osteoporosis.
Conditions
- Osteoporosis
Interventions
RomosozumabDrug
Subjects will receive romosozumab in a specified sequence during the treatment Period.
PlaceboDrug
Subjects will receive Placebo in a specified sequence during the treatment Period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine to the End of Double-Blind PeriodTime frame: From Baseline (Day 1) to the end of the Double-blind Period (Month 6)
- Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Double-Blind PeriodTime frame: From Baseline to the end of the Double-blind Period (Month 6)
- Percentage of Participants With Treatment-emergent Adverse Events for Romosozumab During Overall PeriodTime frame: From Month 7 up to Month 12 (Placebo/Romo) and From Day 1 up to Month 12 (Romo/Romo) + 3-month SFU (up to Month 15)
Locations
30 sites in 1 country. Site status is shown where the registry gives one.
Op0002 20040
Beijing, China
Op0002 20115
Beijing, China
Op0002 20125
Beijing, China
Op0002 20127
Beijing, China
Op0002 20128
Beijing, China
Op0002 20130
Beijing, China
Op0002 20131
Beijing, China
Op0002 20157
Beijing, China
Op0002 20021
Chengdu, China
Op0002 20133
Chengdu, China
Op0002 20137
Chengdu, China
Op0002 20205
Foshan, China
Op0002 20117
Guangzhou, China
Op0002 20124
Guangzhou, China
Op0002 20209
Nanchang, China
Op0002 20135
Nanjing, China
Op0002 20202
Pingxiang, China
Op0002 20199
Rui’an, China
Op0002 20116
Shanghai, China
Op0002 20118
Shanghai, China
Op0002 20121
Shanghai, China
Op0002 20123
Shanghai, China
Op0002 20129
Shanghai, China
Op0002 20119
Suzhou, China
Op0002 20204
Suzhou, China
Op0002 20122
Tianjin, China
Op0002 20136
Tianjin, China
Op0002 20120
Wuhan, China
Op0002 20134
Yueyang, China
Op0002 20132
Zhengzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.